Risk of neutropenia in inflammatory bowel disease patients treated with TNF inhibitors: A single-center, retrospective cohort study

BACKGROUND/AIM: Tumor necrosis factor inhibitors (TNFi) have become the mainstay of treatment in moderate-to-severe cases of inflammatory bowel disease (IBD). Neutropenia has been reported in patients receiving TNFi for IBD and other diseases. In this study, we aimed to ascertain the relationship be...

Descripción completa

Detalles Bibliográficos
Autores principales: AlAskar, Dimah, AlSardi, Mais, Al Sulais, Eman, Mosli, Mahmoud, AlAmeel, Turki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580728/
https://www.ncbi.nlm.nih.gov/pubmed/32496224
http://dx.doi.org/10.4103/sjg.SJG_41_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580728/
https://www.ncbi.nlm.nih.gov/pubmed/32496224
http://dx.doi.org/10.4103/sjg.SJG_41_20

Ejemplares similares